Introduction to the CancerTools.org Organoid Portfolio

    Published by on

    Patient-derived tumour Organoids

    Organoids are unique self-organising 3D microscopic structures derived from cells that represent a physiologically relevant in vitro model systems as they preserve the genomic, physiological characteristics and multicellularity of the equivalent in vivo tissue.

     

    Explore our Organoid collection

    1
    • Available cancer patient-derived organoids (PDOs) are 3D in vitro multicellular models established from a range of human tumour tissues

    • Represent a novel in vitro platform for basic biological research and potential applications in drug testing and molecular medicine

    • Use in various applications can complement existing experimental models
    1
    • Prof. Motoki Takagi and his group from Fukushima Medical University (FMU) have used an independently developed method to establish F-PDOs

    • Recapitulate characteristics of in vivo tumours

    • Employed protocol does not involve enzyme treatment of the clinical material or use of extracellular matrix – the F-PDOs are cultured in suspension
    1
    • Extensively characterised

    • Comprehensive gene expression, whole-exome sequencing and morphological analyses confirm the F-PDOs retain parental tissue characteristics for extended period of time in culture and after cryopreservation

    • Can be employed prior to using high-cost and time-consuming in vivo models such as patient derived xenografts (PDXs)

     

    Key Features

    RLUN21_herceptin only_3h_10bai - with text-2

    • ​Preserve parental tissue genetic profile and morphology: various characterisation tests confirm F-PDOs retain parental tissue genetic profile and morphology​

    • Amenable to extended culture duration: genetically and phenotypically stable for 6 -12 months in culture and after cryopreservation

    • Suspension culture: no extracellular matrix required

    • In  vivo tumorigenesis: suitable for PDX mouse development - gene expression profiles of the xenografts are similar to those of their source F-PDOs and tissues 

    • Suitable for various assays: F-PDOs can be used to establish high-throughput assays to evaluate anticancer agents and antibodies

    • Well-characterized with annotation data: the organoids have been characterised using comprehensive gene expression, whole-exome sequencing and morphological analyses

     

    Applications​

    HubSpot Video
    • Disease modelling 
    • Anticancer agents discovery and development
    • Immuno-oncology assays
    • Compounds’ safety and toxicity testing
    • 3D imaging

     

     

     

     

    Explore our Organoid collection

     
    Tags:
    Back to Blog

    Related Articles